NLM Digital Collections

Search

Start Over Subjects Comparative Effectiveness Research ✖Remove constraint Subjects: Comparative Effectiveness Research Subjects Humans ✖Remove constraint Subjects: Humans Subjects Randomized Controlled Trials as Topic ✖Remove constraint Subjects: Randomized Controlled Trials as Topic

1. Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, July 17, 2017
Subject(s):
Anabolic Agents -- therapeutic use
Antibodies, Monoclonal, Humanized -- therapeutic use
Osteoporosis, Postmenopausal -- drug therapy
Parathyroid Hormone-Related Protein -- therapeutic use
Anabolic Agents -- adverse effects
Anabolic Agents -- economics
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Bone Density Conservation Agents -- adverse effects
Bone Density Conservation Agents -- economics
Bone Density Conservation Agents -- therapeutic use
Comparative Effectiveness Research
Diphosphonates -- adverse effects
Diphosphonates -- economics
Diphosphonates -- therapeutic use
Osteoporotic Fractures -- prevention & control
Parathyroid Hormone-Related Protein -- adverse effects
Parathyroid Hormone-Related Protein -- economics
Randomized Controlled Trials as Topic
Teriparatide -- adverse effects
Teriparatide -- economics
Teriparatide -- therapeutic use
Humans
United States

2. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):
Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States

3. Controversies in the management of patients with type 2 diabetes: final report

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 2014
Subject(s):
Comparative Effectiveness Research
Diabetes Mellitus, Type 2 -- drug therapy
Disease Management
Blood Glucose -- analysis
Blood Glucose -- metabolism
Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
Drug Therapy, Combination
Hemoglobin A, Glycosylated -- analysis
Hypoglycemic Agents -- administration & dosage
Hypoglycemic Agents -- therapeutic use
Insulin -- therapeutic use
Metformin -- administration & dosage
Metformin -- therapeutic use
Monitoring, Ambulatory
Randomized Controlled Trials as Topic
Receptors, Glucagon -- agonists
Sulfonylurea Compounds -- administration & dosage
Sulfonylurea Compounds -- therapeutic use
Treatment Outcome
Humans
New England
United States

4. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: comparative clinical effectiveness and value : evidence report

Author(s):
Pearson, Steven D., author
Banken, Reiner, author
Chapman, Rick, author
Russo, Elizabeth T., author
Loos, Anne M., author
Emond, Sarah K., author
Segel, Celia S., author
Ollendorf, Daniel A., author
Chhatwal, Jagpreet, author
Hur, Chin, author
Klebanoff, Matthew, author
Samur, Sumeyye K., author
Publication:
Boston, MA : Institute for Clinical and Economic Review, July 26, 2016
Subject(s):
Bile Acids and Salts -- agonists
Comparative Effectiveness Research
Fatty Liver -- drug therapy
Bile Acids and Salts -- adverse effects
Diabetes Mellitus, Type 2
Dyslipidemias
Liver Cirrhosis -- prevention & control
Quality of Life
Randomized Controlled Trials as Topic
Humans
United States

5. Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report

Author(s):
Pearson, Steven D., author
Banken, Reiner, author
Chapman, Rick, author
Emond, Sarah K., author
Loos, Anne M., author
Russo, Elizabeth T., author
Segel, Celia S., author
Ollendorf, Daniel A., author
Chhatwal, Jagpreet, author
Hur, Chin, author
Klebanoff, Matthew, author
Samur, Sumeyye, author
Publication:
Boston, MA : Institute for Clinical and Economic Review, March 2016
Subject(s):
Bile Acids and Salts -- agonists
Cholangitis -- drug therapy
Comparative Effectiveness Research
Value-Based Purchasing
Benchmarking
Bile Acids and Salts -- adverse effects
Bile Acids and Salts -- economics
Cost-Benefit Analysis
Liver Cirrhosis -- prevention & control
Liver Transplantation
Pruritus
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

6. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, December 2 2016
Subject(s):
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Psoriasis -- drug therapy
Adalimumab -- therapeutic use
Benchmarking
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Interleukin-12 -- antagonists & inhibitors
Interleukin-17
Interleukin-23 -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors
Phototherapy
Psoriasis -- immunology
Psoriasis -- therapy
Randomized Controlled Trials as Topic
Severity of Illness Index
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Ustekinumab -- therapeutic use
Value-Based Purchasing
Humans
United States

7. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

8. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States